Journal of Bone Research
Open Access

Understanding the Role of Adipokines in Bone Metabolism

Richard Pastrello^{* *}Correspondence: Richard Pastrello, Department of Medicine, Boston University School of Medicine, Boston, USA, Email:

Author info »

Description

Bone metabolism is a complex process that involves continuous bone remodeling, which is crucial for maintaining bone health and preventing various bone disorders. Adipokines, a group of cytokines secreted by adipose tissue, have been shown to play a significant role in bone metabolism.

Adipokines and bone metabolism

Adipokines are a group of bioactive molecules secreted by adipose tissue that have been shown to have a wide range of physiological functions. Adipokines such as leptin, adiponectin, and resistin have been shown to regulate bone metabolism by influencing osteoblast and osteoclast activity.

Leptin, one of the most extensively studied adipokines, has been shown to have a significant impact on bone metabolism. Leptin acts on the hypothalamus to regulate food intake and energy expenditure. Leptin receptors are also present in bone cells, and leptin has been shown to promote bone formation by stimulating osteoblast differentiation and mineralization. Moreover, leptin has been shown to inhibit bone resorption by reducing the activity of osteoclasts. Leptin deficiency in humans and animals is associated with decreased bone mineral density and increased fracture risk, suggesting that leptin plays an essential role in maintaining bone health [1-3].

Adiponectin is another adipokine that has been shown to have a significant impact on bone metabolism. Adiponectin is involved in glucose metabolism and insulin sensitivity, and its deficiency has been linked to the development of metabolic disorders such as type 2 diabetes. Recent studies have shown that adiponectin also plays a crucial role in bone metabolism by regulating osteoblast and osteoclast activity. Adiponectin deficiency in mice has been shown to result in decreased bone mineral density, reduced bone strength, and increased bone resorption. Adiponectin appears to promote osteoblast differentiation and mineralization while inhibiting osteoclast activity. Thus, adiponectin has been suggested to have a protective effect on bone health [4].

Resistin is another adipokine that has been shown to regulate bone metabolism. Resistin has been implicated in the development of insulin resistance, inflammation, and obesity. Recent studies have shown that resistin also plays a role in bone metabolism by regulating osteoblast and osteoclast activity. Resistin has been shown to inhibit osteoblast differentiation and mineralization while promoting osteoclast activity. Thus, resistin has been suggested to have a negative impact on bone health.

Leptin is an adipokine that is well-known for its effects on regulating appetite and energy metabolism. It also influences bone formation and resorption by regulating osteoblast and osteoclast activity, respectively. Leptin signaling has been shown to increase bone mass in rodents, and leptin deficiency in humans is associated with low bone density.

Adiponectin is another adipokine that has been linked to bone health. Studies have found that adiponectin levels are negatively correlated with bone mineral density and bone formation markers in humans. Adiponectin inhibits osteoblast differentiation and promotes osteoclast formation and activity, leading to reduced bone formation and increased bone resorption [5-7].

Resistin is a relatively new adipokine that has been shown to promote osteoclast differentiation and activity, leading to increased bone resorption. Some studies have also reported that resistin inhibits osteoblast differentiation and bone formation.

Adipokines and bone diseases

Several bone diseases are associated with adipokine dysregulation. For instance, osteoporosis, a common bone disease characterized by decreased bone mineral density and increased fracture risk, has been linked to leptin deficiency. Leptin deficiency in humans and animals is associated with decreased bone mineral density and increased fracture risk, suggesting that leptin plays an essential role in maintaining bone health.

Type 2 diabetes is another metabolic disorder that has been linked to adipokine dysregulation. Adiponectin deficiency is common in individuals with type 2 diabetes and has been linked to the development of bone fragility. Adiponectin deficiency in mice has been shown to result in decreased bone mineral density, reduced bone strength, and increased bone resorption, suggesting that adiponectin plays a crucial role in maintaining bone health. Obesity, a common health problem worldwide, has also been linked to adipokine dysregulation and the development of bone disorders [8,9].

Implications for diagnosis and treatment

The connection between bone metabolism and adipokines has important implications for the diagnosis and treatment of bonerelated disorders [10]. For example, measuring levels of adipokines in the blood could provide important information about the risk of developing osteoporosis or other bone-related disorders. Similarly, treatments that target specific adipokines could be developed to treat these disorders.

Conclusion

Bone metabolism and adipokines are two important areas of research that are increasingly being recognized for their connection and their impact on overall health. Understanding the complex relationship between these two areas of research is essential for the development of effective diagnostic and treatment strategies for bone-related disorders. Further research in this area is needed to fully understand the mechanisms underlying the connection between bone metabolism and adipokines, and to develop more targeted and effective treatments for these disorders.

References

1. Conde J, Scotece M, Abella V, López V, Pino J, Gómez-Reino JJ, et al. Basic aspects of adipokines in bone metabolism. Clin Rev Bone Miner Metab. 2015;13:11-19.

   [Crossref] [Google Scholar]

2. Pepe J, Cipriani C, Cilli M, Colangelo L, Minisola S. Adipokines and bone metabolism: An interplay to untangle. J Endocrinol Invest. 2016;39:1359-1361.

   [Crossref] [Google Scholar] [PubMed]

3. Scotece M, Conde J, Abella V, Lopez V, Pino J, Lago F, et al. Bone metabolism and adipokines: Are there perspectives for bone diseases drug discovery?. Expert Opin Drug Discov. 2014;9(8):945-957.

   [Crossref] [Google Scholar] [PubMed]

4. Liu Y, Song CY, Wu SS, Liang QH, Yuan LQ, Liao EY. Novel adipokines and bone metabolism. Int J Endocrinol. 2013;2013.

   [Crossref] [Google Scholar] [PubMed]

5. Magni P, Dozio E, Galliera E, Ruscica M, Corsi MM. Molecular aspects of adipokine-bone interactions. Curr Mol Med. 2010;10(6):522-532.

   [Crossref] [Google Scholar] [PubMed]

6. Wucher H, Ciangura C, Poitou C, Czernichow S. Effects of weight loss on bone status after bariatric surgery: Association between adipokines and bone markers. Obes Surg. 2008;18:58-65.

   [Crossref] [Google Scholar] [PubMed]

7. Chen XX, Yang T. Roles of leptin in bone metabolism and bone diseases. J Bone Miner Metab. 2015;33:474-485.

   [Crossref] [Google Scholar] [PubMed]

8. Barbour KE, Zmuda JM, Boudreau R, Strotmeyer ES, Horwitz MJ, Evans RW, et al. Adipokines and the risk of fracture in older adults. J Bone Miner Res. 2011;26(7):1568-1576.

   [Crossref] [Google Scholar] [PubMed]

9. Neumann E, Junker S, Schett G, Frommer K, Müller-Ladner U. Adipokines in bone disease. Nat Rev Rheumatol. 2016;12(5):296-302.

   [Crossref] [Google Scholar] [PubMed]

10. Scotece M, Conde J, Vuolteenaho K, Koskinen A, Lopez V, Gomez-Reino J, et al. Adipokines as drug targets in joint and bone disease. Drug Discov Today. 2014;19(3):241-258.

    [Crossref] [Google Scholar] [PubMed]